Fluoroquinolone Resistance Among Gram-negative Urinary Tract Pathogens: Global Smart Program Results, 2009-2010

Overview

Journal Open Microbiol J

Publisher Bentham Open

Specialty Microbiology

Date 2012 Sep 25

PMID 23002406

Citations 23

Authors

Sam Bouchillon

Daryl J Hoban

Robert Badal

Stephen Hawser

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the rates of fluoroquinolone resistant (FQR) in gram-negative bacilli urinary tract infections (UTIs) in a global population.

Methods: The Study for Monitoring Antimicrobial Resistance Trends (SMART) collected 1,116 FQR gram-negative urinary pathogens from hospitalized patients in 33 countries during 2009-2010. Amikacin, ertapenem, and imipenem were the most active agents tested against FQR UTI pathogens, including extended-spectrum beta-lactamase producers.

Results: FQR rates vary widely country to country with a range of 6% to 75%. Regional FQR rates were 23.5% in North America, 29.4% in Europe, 33.2% in Asia, 38.7% in Latin America, and 25.5% in the South Pacific.

Conclusions: These observations suggest that fluoroquinolones may no longer be effective as first-line therapy for gram-negative UTI in hospitalized patients.

Citing Articles

Application of Precision Medicine Concepts in Ambulatory Antibiotic Management of Acute Pyelonephritis.

Pizzuti M, Tsai Y, Winders H, Bookstaver P, Al-Hasan M Pharmacy (Basel). 2023; 11(6).

PMID: 37987379 PMC: 10661281. DOI: 10.3390/pharmacy11060169.

Isolation and drug susceptibility pattern of uropathogens in Saudi diabetic and non-diabetic patients with urinary tract infection.

Mirza Sain Z, Rafeeq M, Murad H, Hussain M Bioinformation. 2023; 18(8):710-717.

PMID: 37323552 PMC: 10266366. DOI: 10.6026/97320630018710.

Detection of tem-1 and class-1 integrons in multidrug resistant uropathogens from HIV patients with asymptomatic bacteriuria in a Tertiary Care Hospital, SouthWest Nigeria.

Ajala O, Odetoyin B, Owojuyigbe T, Onanuga A Afr Health Sci. 2022; 22(1):475-485.

PMID: 36032498 PMC: 9382535. DOI: 10.4314/ahs.v22i1.56.

Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant .

Balasubramaniyan S, Irfan N, Umamaheswari A, Puratchikody A RSC Adv. 2022; 8(42):23629-23647.

PMID: 35540291 PMC: 9081776. DOI: 10.1039/c8ra01854e.

A strategy design based on antibiotic‑resistance and plasmid replicons genes of clinical Escherichia coli strains.

Liu J, Lin X, Soteyome T, Ye Y, Chen D, Yang L Bioengineered. 2022; 13(3):7500-7514.

PMID: 35259054 PMC: 9208507. DOI: 10.1080/21655979.2022.2047543.

References

van der Mee-Marquet N, Savoyen P, Domelier-Valentin A, Mourens C, Quentin R . CTX-M-type fluoroquinolone-resistant Escherichia coli: analysis of the colonization of residents and inanimate surfaces 1 year after a first case of urinary tract infection at a nursing home in France. Infect Control Hosp Epidemiol. 2010; 31(9):968-70. DOI: 10.1086/655835. View

Lewis 2nd J, Herrera M, Wickes B, Patterson J, Jorgensen J . First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother. 2007; 51(11):4015-21. PMC: 2151438. DOI: 10.1128/AAC.00576-07. View

van der Starre W, Van Nieuwkoop C, Paltansing S, Vant Wout J, Groeneveld G, Becker M . Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. 2010; 66(3):650-6. DOI: 10.1093/jac/dkq465. View

Shigemura K, Arakawa S, Miura T, Nakano Y, Tanaka K, Fujisawa M . Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections. Jpn J Infect Dis. 2008; 61(3):226-8. View

Urban C, Mariano N, Bradford P, Tuckman M, Segal-Maurer S, Wehbeh W . Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn Microbiol Infect Dis. 2010; 66(4):402-6. DOI: 10.1016/j.diagmicrobio.2009.11.012. View

Pitout J, Laupland K . Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008; 8(3):159-66. DOI: 10.1016/S1473-3099(08)70041-0. View

Karlowsky J, Hoban D, DeCorby M, Laing N, Zhanel G . Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006; 50(6):2251-4. PMC: 1479132. DOI: 10.1128/AAC.00123-06. View

Rattanaumpawan P, Tolomeo P, Bilker W, Fishman N, Lautenbach E . Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. J Hosp Infect. 2010; 76(4):324-7. PMC: 2962678. DOI: 10.1016/j.jhin.2010.05.023. View

Lagace-Wiens P, Nichol K, Nicolle L, Decorby M, McCracken M, Alfa M . ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba. Can J Infect Dis Med Microbiol. 2008; 18(2):133-7. PMC: 2533543. DOI: 10.1155/2007/848194. View

10.

Zhanel G, Hisanaga T, Laing N, DeCorby M, Nichol K, Weshnoweski B . Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006; 27(6):468-75. DOI: 10.1016/j.ijantimicag.2006.02.009. View

11.

Mac Aogain M, Mooij M, Adams C, Clair J, OGara F . Emergence of extended-spectrum beta-lactamase and fluoroquinolone resistance genes among Irish multidrug-resistant isolates. Diagn Microbiol Infect Dis. 2010; 67(1):106-9. DOI: 10.1016/j.diagmicrobio.2009.12.017. View

12.

Castanheira M, Mendes R, Rhomberg P, Jones R . Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist. 2008; 14(3):211-6. DOI: 10.1089/mdr.2008.0827. View

13.

Aypak C, Altunsoy A, Duzgun N . Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. Ann Clin Microbiol Antimicrob. 2009; 8:27. PMC: 2770515. DOI: 10.1186/1476-0711-8-27. View